{"disease":{"id":"multiple-myeloma-progression","name":"multiple myeloma progression"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07032129","title":"Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Essen Biotech","has_results":false},{"nct_id":"NCT03428373","title":"Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":57,"lead_sponsor_name":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","has_results":false},{"nct_id":"NCT03672253","title":"CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Second Affiliated Hospital of Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT03601624","title":"Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":18,"lead_sponsor_name":"Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado","has_results":false},{"nct_id":"NCT03687125","title":"Tinostamustine Conditioning and Autologous Stem Cell","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Mundipharma-EDO GmbH","has_results":true}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}